1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
3.64%
Cash & equivalents yoy growth near the Drug Manufacturers - Specialty & Generic median of 3.64%. Seth Klarman would see it as in line with peers. Evaluate why the company holds additional cash.
71.52%
Short-term investments yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
25.69%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.75%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
830.66%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 1.57%. Jim Chanos might see a serious red flag in ballooning receivables.
36.09%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.11%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-76.58%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
41.18%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 2.15%. Joel Greenblatt sees a potential liquidity edge if well allocated.
77.47%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
11980.78%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
5861.67%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
8503.96%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-0.17%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
4.40%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
141.15%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
95.84%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 1.37%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
44.26%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
453.74%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
221.86%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
77.04%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
527605400.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
119.78%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 4.33%. Jim Chanos suspects potential working capital strain.
-2.27%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
108.17%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
112.78%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 1.55%. Jim Chanos suspects an alarming rise in overall leverage.
92.66%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
75.80%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-0.74%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
42.71%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
91.05%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 1.87%. Joel Greenblatt sees stronger equity growth vs. peers.
95.84%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 1.29%. Joel Greenblatt sees more aggressive expansions than peers.
27.74%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
19.54%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
2.56%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
